Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Tekton Research LLC

Neither a doctor nor a teaching hospital

Research payments

$9,554,855

1,718 payments

Through program year 2025, Tekton Research LLC is reported as receiving $9,554,855 in research payments, across 1,718 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $7,496,682 1,456
2024 Research $880,282 102
2023 Research $1,177,890 160

Breakdown

Who paid Research payments · program years 2023–2025
  1. Moderna TX, Inc. $6,486,024 1,243 payments
  2. GlaxoSmithKline, LLC. $1,499,763 241 payments
  3. Pfizer Inc. $535,611 119 payments
  4. AbbVie, Inc. $457,001 46 payments
  5. Amgen Inc. $327,821 10 payments
  6. Genentech, Inc. $166,605 39 payments
  7. Merz Pharmaceuticals, LLC $25,590 6 payments
  8. Otsuka Pharmaceutical Development & Commercialization, Inc. $20,769 1 payment
  9. Bausch Health US, LLC $14,000 3 payments
  10. Sumitomo Pharma America, Inc. $13,357 7 payments
Studies the money was for Research payments · program years 2023–2025
  1. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $2,289,770 327 payments
  2. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $2,211,193 326 payments
  3. A Phase I/II Observer-Blind, Randomized, Multi-Center Trial to Evaluat $665,609 45 payments
  4. A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants $545,220 214 payments
  5. A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age $474,085 65 payments
  6. A Phase 3 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of A Combined Modified Rna Vaccine Candidate Against Covid19 and Influenza in Healthy Individuals $429,867 15 payments
  7. A Phase 1, Open-Label, Randomized, Parallel Group, Single-Dose Clinica $282,529 24 payments
  8. Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age $232,806 27 payments
  9. A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 $210,810 101 payments
  10. A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $166,173 69 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record